• Tuberculosis and Respiratory Diseases
• /
• 제67권3호
• /
• pp.221-225
• /
• 2009

Background: Pain is one of the most troublesome problems caused by malignancy. We evaluated the change in pain status according to observance of NCCN guidelines in lung cancer patients. Methods: Lung cancer patients complaining of pain at admission were examined. The pain was assessed with visual analogue scale (VAS) for 20 days and moderate-to-severe pain was defined as more than VAS level 3. The guideline observance was classified as high (more than 80%), medium (50~79%) and low (less than 50%). Results: Among the total 91 lung cancer patients with pain, 34 patients (37%) had moderate-to-severe pain. Their average VAS score at admission was 5.6. It decreased to 2.9 after a 20-day period of pain management. The time to reach a VAS less than 3 was 3 days in a high guideline observance group, while it took 6 days in a low observance group. In addition, the pain in the high observance group was controlled to less than 3 VAS level in 86% of patients, whereas only 25% of patients in the low observance group succeeded. Conclusion: Pain was more effectively controlled when the dose of drugs was modified according to NCCN guidelines in lung cancer patients indicating the importance of guideline observance in pain management.

• Radiation Oncology Journal
• /
• 제34권3호
• /
• pp.160-167
• /
• 2016

In oncologic practice, treatment guidelines provide appropriate treatment strategies based on evidence. Currently, many guidelines are used, including those of the European Association for the Study of the Liver and European Organization for Research and Treatment of Cancer (EASL-EORTC), National Comprehensive Cancer Network (NCCN), Asia-Pacific Primary Liver Cancer Expert (APPLE), and Korean Liver Cancer Study Group and National Cancer Centre (KLCSG-NCC). Although radiotherapy is commonly used in clinical practice, some guidelines do not accept it as a standard treatment modality. In this review, we will investigate the clinical practice guidelines currently used, and discuss the application of radiotherapy.

• 한국콘텐츠학회논문지
• /
• 제14권5호
• /
• pp.458-467
• /
• 2014

통증은 암 환자들이 겪는 가장 흔하며 고통스러운 증상중의 하나이며, 암의 진단 초기에 있거나 적극적인 항암 치료를 받고 있는 환자의 30~50%, 진행성인 경우에는 약 60~70%, 말기의 경우에는 80~90% 정도가 통증으로 고통 받고 있는 것으로 알려져 있다. 그러나 이러한 암 환자들에게 있어 체계적이고 사용하기 쉬운 통증 관리 프로그램이 없어 이에 대한 필요성이 요구되고 있다. 본 논문은 암 수술 생존자 및 퇴원 환자가 겪는 통증의 관리에 있어 돌발성 통증 발생 시 신속히 통증을 완화할 수 있는 서비스를 위한 암 통증 자가 관리 알고리즘을 제안한다. 제안 알고리즘은 타당한 가이드라인 정립을 위해 조사지와 평가지, 그리고 NCCN(National Comprehensive Cancer Network) 가이드라인을 참조하였으며, 설계된 알고리즘의 평가를 위해 20명의 암 환자 실험군을 대상으로 한 달간 시범 서비스를 수행하였다. 제안 알고리즘을 평가하기 위하여 시범 서비스 결과를 전문 의료진을 통해 검토한 결과, 90%의 적합성 판단을 도출하여 제안 알고리즘의 실효성을 검증하였다. 의료 전문의 결과 부적합 판단의 경우 통증 일기의 관리에서 적합한 결과를 도출하지 못했으며 이에 대한 향후 연구로 사용자 맞춤형의 통증 일기 알고리즘을 추가로 연구하고자 한다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권17호
• /
• pp.7837-7841
• /
• 2015

Objective: To assess the safety of Liena polypeptide injection (produced by JILIN FSENS PHARMACEUTICAL CO.,LTD) combined with chemotherapy in treating patients with advanced cancers. Method: A consecutive cohort of patients with advanced cancers were treated with Liena polypeptide injection combined with chemotherapy. And chemotherapy for patients with advanced cancers were adopted from regimens suggested by NCCN guideline. Liena polypeptide injection was intravenously injected at a dosage of 2ml plus 100ml normal saline for continuous 7 days during chemotherapy as one course. After at least two courses of treatment, safety and side effects were evaluated. Results: There were 20 female and 14 male patients with advanced cancer recruited into this study, including 10 patients with breast, 8 patients with colorectal, 8 patients with lung, 4 patients with gastric, and 1 patient with esophageal cancer, as well as 1 patient with non-Hodgkin's lymphoma, 1 patient with low pharyngeal and 1 patient with urethral cancer. The median age of patients was 59 (40-82) years. Incidences of Grade 1 to 2 myelosuppression was observed in 5/34 patients, and Grade 1 to 2 elevation of hepatic enzyme was recorded in 3/34 patients. Adverse effects on the gastrointestinal tract were documented in 5/34 patients, and were Grade 1. No Grade 3-4 toxicities were diagnosed. No treatment related death was found. Conclusions: Liena polypeptide injection combined with chemotherapy was safe in treating several sites of tumors, that mainly included lung, colorectal and breast cancer. However, further study should be conducted to clarify the effectiveness of this treatment.

• Journal of Digestive Cancer Research
• /
• 제5권1호
• /
• pp.62-65
• /
• 2017

2013년 실제 임상에 Gemcitabine과 nab-paclitaxel 병용요법이 적용된 후 NCCN Guideline에서 절제 불가능한 췌장암 환자에서 일차적으로 선택할 수 있는 약제로 제시하고 있다. 이 병용요법으로 인한 가장 흔한 Grade 3 부작용으로는 호중구감소증, 피로, 말초신경병증이 보고되었으며, 심장독성은 흔하지 않다. 본 증례에서는 심장표지자의 상승 및 심초음파에서의 우측관상동맥의 허혈 손상이 확인되어 병용요법으로 인한 심장 허혈 손상 및 심낭삼출물이 발생하여, 심장성 쇼크로 사망하였을 것으로 추정해 볼 수 있다. Gemcitabine과 nab-paclitaxel에 의한 심장 허혈 손상의 더 많은 증례 보고 및 연구가 필요하며, 병용요법을 투여 받는 환자들에 대한 심장독성에 대하여 주의 깊은 관찰이 필요할 것으로 생각된다.